Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension

(RTTNews) - Novo Nordisk A/S (NVO), a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA)...

By Dhallo News · October 3, 2026 at 6:42 PM IST

(RTTNews) - Novo Nordisk A/S (NVO), a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) informed the company that its Biologics License Application (BLA) review of denecimig for haemophilia A treatment remains ongoing, with no new regulatory timel

SOURCE: Nasdaq

ORIGINAL REPORT: Click here

DHALLO EDITORIAL STATUS: Aggregated & reviewed

Have feedback on this article?Report error or suggestion

Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension

Read More from Markets

Can AI Outrun America’s Deficit Problem?

Babcock & Wilcox Enterprises, Inc. - Corporate Bond Price Target Increased by 34.46% to $95.61

Northern Trust Corporation - Preferred Stock Price Target Increased by 11.53% to $20.55

5 minutes. The news that matters.